Skip to main navigation
Go to Cumberland Pharmaceuticals, Inc. homepage
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
Contact
Contact

Corporate Update

November 2026       

To Our Shareholders, Employees & Partners:      

The third quarter of 2026 marked the first period of Cumberland’s operations following the close of our Strategic Transaction and our pivot to a focus on the development of new medicines for the future. As a result, we recently announced the decision to submit a New Drug Application (NDA) to the FDA for approval of our ifetroban product candidate as a potential treatment for patients with the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). As discussed in that announcement, we decided to proceed with the submission in order to help address the important unmet medical need in patients suffering from the symptoms associated with this lifethreatening disease.

Meanwhile, we continue to support the transition of our commercial portfolio and team to Apotex Health, based on our commitments associated with the Strategic Transaction. The completion of that agreement strengthened our balance sheet, simplified our business model and allowed us to concentrate our resources on our clinical pipeline, which we believe is a source of potential long-term value for our shareholders.

Following the Transaction, we completed a strategic planning process to take a fresh look at and define who we are and where we are headed. Our resulting refined mission statement reflects our emphasis on innovation:

Advancing new therapies that address significant unmet medical needs.

Ifetroban remains our top development priority, with our Duchenne program leading the way. Building on the positive results from our Phase 2 FIGHT DMD® trial, this fall we held a pre-NDA meeting with the FDA and subsequently received their agreement for a rolling review of our NDA. The program has previously received Fast Track, Orphan Drug and Rare Pediatric Disease designations from the agency.

We are also advancing ifetroban in other conditions with limited treatment options. We recently announced topline findings from our Phase 2a trial in Systemic Sclerosis (SSc) with favorable safety and tolerability results. We will next complete correlative biomarker studies using specimens collected during the trial, along with an evaluation of cardiac imaging from patients continuing on the study’s open-label extension.

Enrollment in our Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF) continues to progress - with interim efficacy results as the next milestone. Beyond our company-sponsored programs, we collaborated with Vanderbilt Health on a Phase 2a trial evaluating ifetroban for the prevention of cancer metastasis in patients with high-risk solid tumors. Based on the positive findings from that study, we are now developing plans for a follow-up study.

As we proceed through the final quarter of 2026, I want to thank our Board for their leadership, our employees for their dedicated efforts and our shareholders for their continued support as we pursue our new mission.

All the best,

AJ's Initials

Please see our corporate website at www.cumberlandpharma.com for links to our product websites for full prescribing and safety information on our brands and for our SEC filings that contain the risk factors associated with our business.

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy
Accessibility Statement
Terms of Use